Literature DB >> 27133561

Syndrome disintegration: Exome sequencing reveals that Fitzsimmons syndrome is a co-occurrence of multiple events.

Christine M Armour1,2, Amanda Smith1,2, Taila Hartley2, Jodi Warman Chardon1,2, Sarah Sawyer1,2, Jeremy Schwartzentruber3, Raoul Hennekam4, Jacek Majewski5, Dennis E Bulman2, Mohnish Suri6, Kym M Boycott1,2.   

Abstract

In 1987 Fitzsimmons and Guilbert described identical male twins with progressive spastic paraplegia, brachydactyly with cone shaped epiphyses, short stature, dysarthria, and "low-normal" intelligence. In subsequent years, four other patients, including one set of female identical twins, a single female child, and a single male individual were described with the same features, and the eponym Fitzsimmons syndrome was adopted (OMIM #270710). We performed exome analysis of the patient described in 2009, and one of the original twins from 1987, the only patients available from the literature. No single genetic etiology exists that explains Fitzsimmons syndrome; however, multiple different genetic causes were identified. Specifically, the twins described by Fitzsimmons had heterozygous mutations in the SACS gene, the gene responsible for autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS), as well as a heterozygous mutation in the TRPS1, the gene responsible in Trichorhinophalangeal syndrome type 1 (TRPS1 type 1) which includes brachydactyly as a feature. A TBL1XR1 mutation was identified in the patient described in 2009 as contributing to his cognitive impairment and autistic features with no genetic cause identified for his spasticity or brachydactyly. The findings show that these individuals have multiple different etiologies giving rise to a similar phenotype, and that "Fitzsimmons syndrome" is in fact not one single syndrome. Over time, we anticipate that continued careful phenotyping with concomitant genome-wide analysis will continue to identify the causes of many rare syndromes, but it will also highlight that previously delineated clinical entities are, in fact, not syndromes at all.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  ARSACS; Fitzsimmons syndrome; Trichorhinophalangeal syndrome type 1; concomitant mutations; exome sequencing; syndrome

Mesh:

Substances:

Year:  2016        PMID: 27133561     DOI: 10.1002/ajmg.a.37684

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

1.  Understanding the Landscape of X-linked Variants Causing Intellectual Disability in Females Through Extreme X Chromosome Inactivation Skewing.

Authors:  Evelyn Quintanilha Vianna; Rafael Mina Piergiorge; Andressa Pereira Gonçalves; Jussara Mendonça Dos Santos; Veluma Calassara; Carla Rosenberg; Ana Cristina Victorino Krepischi; Raquel Tavares Boy da Silva; Suely Rodrigues Dos Santos; Márcia Gonçalves Ribeiro; Filipe Brum Machado; Enrique Medina-Acosta; Márcia Mattos Gonçalves Pimentel; Cíntia Barros Santos-Rebouças
Journal:  Mol Neurobiol       Date:  2020-06-20       Impact factor: 5.590

Review 2.  NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment.

Authors:  Ana Fernandez-Marmiesse; Sofia Gouveia; Maria L Couce
Journal:  Curr Med Chem       Date:  2018-01-30       Impact factor: 4.530

3.  Phenotypic expansion illuminates multilocus pathogenic variation.

Authors:  Ender Karaca; Jennifer E Posey; Zeynep Coban Akdemir; Davut Pehlivan; Tamar Harel; Shalini N Jhangiani; Yavuz Bayram; Xiaofei Song; Vahid Bahrambeigi; Ozge Ozalp Yuregir; Sevcan Bozdogan; Gozde Yesil; Sedat Isikay; Donna Muzny; Richard A Gibbs; James R Lupski
Journal:  Genet Med       Date:  2018-04-26       Impact factor: 8.822

Review 4.  Genome sequencing and implications for rare disorders.

Authors:  Jennifer E Posey
Journal:  Orphanet J Rare Dis       Date:  2019-06-24       Impact factor: 4.123

Review 5.  Uncovering Missing Heritability in Rare Diseases.

Authors:  Tatiana Maroilley; Maja Tarailo-Graovac
Journal:  Genes (Basel)       Date:  2019-04-04       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.